| GlaxoSmithKline AG - Nucala 100 mg/mL, Injektionslösung im Fertigpen |
| 67350 | | 01 | | Nucala 100 mg/mL | | Injektionslösung im Fertigpen | | R03DX09 | | Mepolizumab | | 13.02.2020 | | |
|
| Composition |
| mepolizumabum 100 mg, saccharum, dinatrii phosphas heptahydricus, acidum citricum monohydricum, polysorbatum 80, dinatrii edetas, aqua ad iniectabile q.s. ad solutionem pro 1.0 ml corresp. natrium 0.72 mg. |
| Packungsbestandteile |
| Injektionslösung im Fertigpen | | | | | | | | Active Agent | Dose |
|---|
| Mepolizumabum | 100mg / 1ml |
| | BAG: Active Agent | Dose |
|---|
| Mepolizumabum | 100 mg |
| | | | Inactive agents |
|---|
| Citric Acid Monohydrate | | Dinatrii Edetas | | Disodium Phosphate Heptahydrate | | Polysorbatum 80 | | Saccharum |
| |
|
| Package number | Package Size | EFP | CP | Category | SL | Out of trade (MedRef) |
|---|
| 001 | | 976.63 | 1078.55 | B | SL | No |
|
